Movement Alert｜Twist Bioscience Corp Falls 6.05% in Pre-Market Trading, Earlier Rating Initiations and Lilly TuneLab Collaboration Remain in Focus

Market Focus10-30

On October 30, Twist Bioscience Corp fell 6.05% in Pre-Market Trading, trading at $161.3 per share, with turnover of $145,900.

The recent backdrop remains event-driven: the market has been digesting earlier analyst coverage and the company’s previously announced collaboration with Eli Lilly’s TuneLab, while no stronger new catalyst was evident in the latest public information.

Recent disclosures show Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS assigned a Neutral rating and a $144 price target. Separately, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform, with the collaboration focused on antibody drug discovery. The latest move appears tied to continued capital rotation after that prior attention rather than a fresh standalone announcement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment